Login to Your Account

Tysabri Still Viable: Analyst

Novartis, Serono In MS Race To Market First Oral Therapy

By Randall Osborne

Monday, July 11, 2005

The much-touted multiple sclerosis drug from Biogen Idec Inc., which pumped investors' hopes and then bombed, continues to grab headlines, albeit smaller ones. The drug was pulled from the market in February after it was linked to patient deaths from progressive multifocal leukoencephalopathy.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription